Aska Pharmaceutical Co
Aska Pharmaceutical Co., Ltd., commonly referred to as Aska Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan (JP). Established in 1941, the company has made significant strides in developing innovative healthcare solutions, particularly in the fields of prescription pharmaceuticals and over-the-counter products. With a strong operational presence in Asia and beyond, Aska Pharma focuses on therapeutic areas such as cardiovascular, oncology, and infectious diseases. Their core offerings include unique formulations and advanced drug delivery systems that set them apart in a competitive market. Recognised for their commitment to quality and research, Aska Pharmaceutical has achieved notable milestones, including strategic partnerships and a robust pipeline of new drugs. Their dedication to improving patient outcomes solidifies their position as a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Aska Pharmaceutical Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aska Pharmaceutical Co's score of 31 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aska Pharmaceutical Co's reported carbon emissions
Aska Pharmaceutical Co, headquartered in Japan, has reported its carbon emissions data up to 2023. In this year, the company emitted approximately 6,052,000 kg CO2e from Scope 1 and 2 sources, alongside 8,997,000 kg CO2e from Scope 3 emissions. This marks a reduction in total emissions from previous years, with 2022 figures showing about 6,778,000 kg CO2e from Scope 1, 4,013,000 kg CO2e from Scope 2, and 8,997,000 kg CO2e from Scope 3. In 2021, Aska's total emissions were approximately 12,251,000 kg CO2e, with significant contributions from Scope 1 (7,265,000 kg CO2e) and Scope 3 (10,791,000 kg CO2e). The company has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. Overall, Aska Pharmaceutical Co is actively working towards minimising its carbon emissions, reflecting a growing awareness of climate impact within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 1,732,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,058,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | 00,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aska Pharmaceutical Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
